Amplification primer for detecting drug-resistant mutant gene of HCV (hepatitis c virus) 2a subtype NS5A, application and detection method

Abstract

The invention discloses an amplification primer for detecting a drug-resistant mutant gene of HCV (hepatitis c virus) 2a subtype NS5A, application and a detection method. The amplification primer fordetecting a drug-resistant mutant gene of HCV 2a subtype NS5A comprises a first amplification primer pair, wherein sequences of an upstream primer and a downstream primer in the first amplification primer pair are shown by SEQ ID NO:1 and SEQ ID NO:2 respectively. The amplification primer for detecting a drug-resistant mutant gene of HCV 2a subtype NS5A can be used for analyzing and studying the mutation condition of the HCV gene so as to provide reference for clinical study on drug resistance. When the amplification primer is adopted to perform detection and analysis such as PCR amplification, the effectiveness is high, the detection success rate can reach 100%, the reproducibility is high, and particularly, the minimum detection limit is low, thus the detection of a sample with low HCV RNA concentration is facilitated while the sensitivity is high.

Description

technical field [0001] The invention relates to the field of molecular biology, in particular to an amplification primer for detecting HCV 2a subtype NS5A drug resistance mutation gene, an application and a detection method. Background technique [0002] Hepatitis C is caused by hepatitis C virus (HCV) infection and is mainly transmitted by blood / body fluids. The World Health Organization estimates that 170 million people are infected with HCV worldwide. The anti-HCV positive rate of healthy people in my country is 0.7% to 3.1%, about 38 million people. Due to various factors such as the biological characteristics of the virus and the immune function of the host, it is often difficult for the body's immunity to effectively clear the virus, resulting in about 50% to 80% of HCV-infected patients developing chronic hepatitis, of which 20% to 30% will develop into liver cirrhosis. Every year, 1% to 4% of patients with liver cirrhosis develop hepatocellular carcinoma. Direct a...

AI Technical Summary

Problems solved by technology

Direct anti-HCV agents (DAAs) are mainly inhibitors of HCV viral non-structural proteins (NS3, NS5A, NS5B), and certain mutations in HCV genes can significantly reduce this inhibitory effect

Images